Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bristol Myers Squibb 4Q Results | Contract Pharma

What are you searching for?

Sign in
Financial News

Bristol Myers Squibb 4Q Results

Immuno-oncology portfolio sales drive growth in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol Myers Squibb

4Q Revenues: $12.5 billion +1% 

4Q Earnings: $1.1 billion (earnings were $72 million 4Q24)

FY Revenues: $48.2 billion (flat)

FY Earnings: $7.1 billion (loss of $8.9 billion FY24) 

Comments:  Growth Portfolio revenues were $7.4 billion in the quarter, up 16% primarily driven by the immuno-oncology portfolio, Camzyos, Breyanzi and Reblozyl. Camzyos sales were $353 million, up 59%. Breyanzi sales were $392 million, up 49%. Reblozyl sales were $666 million, up 22%.

Opdivo sales were $2.7 billion in the quarter, up 9%. Orencia sales were $1.0 billion, up 1%. Yervoy sales were up 20% to $810 million. Opdualog sales were up 38% to $350 million. 

Cobenfy sales were $51 million in the quarter and $155 million for the year, up over 200% respectively. Cobenfy, a muscarinic agonist to treat schizophrenia launched in September 2024. It’s the first new treatment option for schizophrenia in 35 years.

Legacy Portfolio revenues were $5.1 billion, down 15%. Eliquis sales were up 8% to $3.5 billion, which helped offset continued generic impact across the remainder of the Legacy Portfolio. Revlimid sales were $602 million, down 55%. Pomalyst/Imnovid sales were $692 million, down 16%. Sprycel sales were down 60% to $79 million. Abraxane sales were down 52% to $84 million.

Earnings for the quarter and year reflect the impact of Acquired IPRD charges of $1.4 billion and $3.7 billion, respectively, primarily driven by the acquisition of Orbital Therapeutics. Licensing income increased from $48 million to $222 million in the quarter and from $122 million to $430 million for the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics